Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000342
  4. Details
NCT00000342 Clinical Trial

Risperidone for the Treatment of Cocaine Dependence - 7

Cocaine-Related Disorders Clinical Trial

Official title:
Risperidone for the Treatment of Cocaine Dependence

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00000342
Other study ID # NIDA-3-0010-7
Secondary ID Y01-3-0010-7
Status Completed
Phase Phase 2
First received September 20, 1999
Last updated January 13, 2017
Start date July 1996
Est. completion date September 1997

Study information
Verified date June 1997
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate clinical safety and pharmacological efficacy in the treatment of cocaine dependence, to evaluate impact of treatment on craving, and to correlate evidence of baseline neurotoxic damage of cocaine with treatment outcome and clinical side-effects.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date September 1997
Est. primary completion date August 1997
Accepts healthy volunteers No
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Risperidone

Locations
Country Name City State
United States Friends Research Institute Los Angeles California

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2
Completed NCT00000280 - Glutaminergic Agents for Cocaine Abuse - 5 Phase 1
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2